OS Therapies updates OST-HER2 metastatic osteosarcoma program
OS Therapies, Inc. said it provided an update on its OST-HER2 metastatic osteosarcoma program and announced upcoming conference attendance by its management team and business development advisors.
New York and Rockville, Maryland--(. - September 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its management team, its business development advisors an…